Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?

详细信息    查看全文

• 作者：Yasemin Ozsurekci^a ; ^{yas.oguz99@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Kubra Aykac^a ; Ali Bulent Cengiz^a ; Cihangul Bayhan^a ; Banu Sancak^b ; Eda Karadag Oncel^a ; Ates Kara^a ; Mehmet Ceyhan^a
• 关键词：Colistin ; Childhood ; Bacterial resistance ; Multidrug resistant (MDR) ; Extremely drug resistant (XDR)
• 刊名：Diagnostic Microbiology & Infectious Disease
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：85
• 期：2
• 页码：233-238
• 全文大小：338 K

文摘

The increasing incidence of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative organisms has led to the reemergence of colistin use. Clinical and demographic data were collected on 94 pediatric patients diagnosed with MDR or XDR gram-negative infections and treated with either a colistin-containing regimen (colistin group) or at least one antimicrobial agent other than colistin (noncolistin group). The overall clinical response rates were 65.8% in the colistin group and 70.0% in the noncolistin group (<em>Pem> = 0.33). The infection-related mortality rates were 11% in the colistin group and 13.3% in the noncolistin group (<em>Pem> = 0.74). There was no statistically significant difference in nephrotoxicity in the colistin and noncolistin groups. Colistin therapy was at least as effective and as safe as beta-lactam antibiotics or quinolones, with or without aminoglycosides, in the treatment of infections caused by gram-negative organisms and may be a therapeutic option in children.